leadf
logo-loader
viewRace Oncology Ltd

Race Oncology's Daniel Tillett details positive preclinical results for Bisantrene in breast cancer

Race Oncology Limited's (ASX:RAC) Daniel Tillett speaks to Proactive's Andrew Scott following the release of positive preclinical results for its Bisantrene drug in breast cancer. It was part of a collaborative research program between Race and The University of Newcastle with the aim of identifying combinations of current breast cancer drugs that when paired with Bisantrene show equivalent efficacy to existing treatment options, but with significantly reduced serious side effects.

Quick facts: Race Oncology Ltd

Price: 1.745 AUD

ASX:RAC
Market: ASX
Market Cap: $225.91 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Race Oncology Ltd named herein, including the promotion by the Company of Race Oncology Ltd in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Race Oncology director sees "extreme, untapped value" in company's cancer drug

Race Oncology (ASX:RAC) non-executive director Dr. John Cullity tells Proactive Investors the specialty pharmaceutical company is working on getting the company's cancer chemotherapy drug, Bisantrene, to market by 2021 or 2022. Dr. Cullity says the drug treats leukemia, and...

on 15/5/18

2 min read